Melatonin regulates intraocular pressure (IOP) whose increase leads to glaucoma and eye nerve degeneration. Aiming at elucidating the role of melatonin receptors in humour production and IOP maintenance, we here demonstrate that glaucoma correlates with disassembly of α 1 -adrenergic/melatonin receptor functional units in cells producing the aqueous humour. Remarkably, α 1 -adrenoceptor-containing complexes do not coupled to the cognate Gq protein and, hence, phenylephrine activation of these receptors does not lead to Ca 2+ mobilization. Functional complexes are significantly decreased in models of glaucoma and, more importantly, in human samples of glaucoma patients (GP). In such glaucomatous conditions phenylephrine produces, via α 1 -adrenoceptor activation, an increase in cytoplasmic [Ca 2+ ] that is detrimental in glaucoma. The results led to hypothesize that using melatonin, a hypotensive agent, plus blockade of α 1 -adrenergic receptors may normalize pressure in glaucoma. Remarkably, co-instillation of melatonin and prazosin, a α 1 -adrenergic receptor antagonist, results in long-term decreases in IOP in a wellestablished animal model of glaucoma. The findings are instrumental to understand the physiological function of melatonin in the eye and its potential to address eye pathologies by targeting melatonin receptors and their complexes.
Introduction
Glaucoma, a pathology characterized by visual field loss, is associated with optic nerve damage (Casson, Chidlow, Wood, Crowston, & Goldberg, 2012) . The main risk factors are inter alia aging, genetic conditions and intraocular pressure (IOP) (Quigley, 2011) . Besides being the second cause of blindness in the World, 61 million people suffer from glaucoma and by 2020 the number may approach 80 million (Quigley & Broman, 2006) .
Normotensive IOP in adults is approximately 16 mmHg. Ocular hypertension is diagnosed when the value exceeds 21 mmHg (Li, Huang, & Zhang, 2018) . Persistent ocular hypertension results in damage of the optic disc, causing degeneration of ganglion cells. The relationship between ocular hypertension and glaucomatous pathology is a well-known phenomenon (Sihota, Angmo, Ramaswamy, & Dada, 2018) . However, despite the current therapeutic arsenal to decrease IOP, ocular hypertension is still the most important risk factor for optic nerve degeneration (Rossetti et al., 2015; Tamm, Braunger, & Fuchshofer, 2015) .
Parasympathomimetics, adrenergic receptor antagonists, carbonic anhydrase inhibitors and prostaglandins reduce ocular hypertension (Hommer, 2010; D. A. Lee & Higginbotham, 2005) although may present notorious side effects (Beckers, Schouten, Webers, van der Valk, & Hendrikse, 2008) . Better and safer interventions include drug co-administration as a way to reduce doses and side effects (Polo, Larrosa, Gomez, Pablo, & Honrubia, 2001; Sakai et al., 2005) .
Anti-glaucomatous compounds reduce aqueous humour formation by the ciliary body thus leading to decreased IOP. In the healthy eye, the control of aqueous humour production is tightly controlled by hormones/neuromodulators, and aging leads to imbalance and increased hydrostatic pressure (Delamere, 2005) . The role of adrenoceptors expressed in the ciliary body seems to be opposite as either α-adrenergic agonists or ß-adrenergic antagonists may decrease IOP (Kiuchi, Yoshitomi, & Gregory, 1992; Murray & Leopold, 1985; Naito, Izumi, Karita, & Tamai, 2001) . Studies in different animal models indicated that epinephrine, i.e. the endogenous agonist, produces a reduction in IOP, which can be blocked by prazosin, a selective α 1 -adrenoceptor antagonist (Funk, Wagner, & Rohen, 1992 ; P. F. Lee, 1958; Moroi, Hao, Inoue-Matsuhisa, Pozdnyakov, & Sitaramayya, 2000) . Interest in melatonin is emerging in ocular diseases as it modulates aqueous humour production in the ciliary body. Thus, this indoleamine has potential in the treatment of ocular hypertension likely by acting via specific receptors: MT 1 and MT 2 (Crooke, Colligris, & Pintor, 2012; Mediero, AlarmaEstrany, & Pintor, 2009 ). The aim of this paper was to decipher in the eye the interplay of melatonin and epinephrine.
Material and methods

Human eye postmortem samples
Three eyes of normal subjects and two of glaucoma patients (GP) came from donations managed by the Balearic Islands tissue bank Foundation. After fixation with 4% paraformaldehyde, frontal sections (10 µm thick) were collected and stored at -20 º until use.
Animals and intraocular pressure measurements
Experiments were performed using female C57BL/6J (n=5) (control) and DBA/2J (n=5) (glaucoma model) mice delivered by Charles River Lab. Institutional and regional Ethic Committees approved all procedures that included ARVO Statement for Ophthalmic and Vision Research. Mice were anesthetized by inhalation of isoflurane and IOP determined as previously described (MartinezAguila, Fonseca, Perez de Lara, .
Cells, fusion proteins and expression vectors
The human non-pigmented ciliary epithelial cell line, 59HCE, was kindly supplied by Dr. CocaPrados (Yale University) and grown in 10% high-glucose Dulbecco's-modified Eagle's medium (Gibco/Invitrogen, Carlsbad, CA). HEK-293T cells were grown in 5% FBS DMEM (Gibco/Invitrogen, Carlsbad, CA) as previously described (Martinez-Pinilla et al., 2017; .
The human cDNAs for the MT 1 , MT 2 and α 1A receptors cloned in pcDNA3.1 were amplified without their stop codons using sense and antisense primers harboring either unique Hind III and BamH1 sites (MT 1 , MT 2 ) or EcoRI and BamHI sites (α 1A ). The fragments were then subcloned to be in frame with a peYFP (YFP) and a pGFP 2 (GFP 2 ) placed on the C-terminal end of the receptor.
Transient transfection and sample preparation for energy-transfer experiments
HEK-293T cells growing in 6-well dishes were transiently transfected with the cDNA encoding for each protein/fusion proteins. Cells were incubated in serum-free medium (4h) with the corresponding cDNA, with polyethylenimine (PEI, 5.47 mM in nitrogen residues) and 150 mM NaCl. The rest of procedure was performed as described elsewhere for FRET, BRET and fluorescence determinations (Hinz et al., 2018; Martinez-Pinilla et al., 2017; Navarro et al., 2018) .
cAMP, calcium determination, ß-arrestin recruitment and label-free dynamic mass redistribution (DMR) assays
For cAMP determination 59HCE cells or HEK-293T cells were detached and re-suspended in medium containing 50 µM zardaverine (2,500 cells/well), pretreated (15 min) with the indicated molecule(s) and stimulated with agonists (15 min) before addition of 0.5 µM forskolin or vehicle. For [Ca 2+ ] determination cells were transfected with the cDNA encoding for the GCaMP6 calcium sensor (3 µg cDNA) using lipofectamine 2000 (Thermo Fisher Scientific). 48 hours after transfection, cells (150,000 cells/well in 96-well black, clear bottom plates) were incubated with Mg 2+ -free Locke's buffer pH 7.4 supplemented with 10 µM glycine and receptor ligands were added as indicated. To determine arrestin recruitment, BRET experiments were performed in HEK-293T cells 48 h after transfection with the cDNA corresponding to β-arrestin-2-Rluc (1 µg) and α 1A -YFP (1,5 µg), or to β-arrestin-2-Rluc (1 µg) and MT 1 -YFP (1,5 µg), or to MT 2 -YFP (1,5 µg) alone or with α 1A (0.05 to 0,5 µg). Further details on procedures are elsewhere described (Martinez-Pinilla et al., 2017; Navarro et al., 2018) .
Immunofluorescence and in situ proximity ligation (PLA) assays
Frozen sections from healthy and glaucoma subjects were rinsed in phosphate buffer saline (PBS) 1X and permeabilized with PBS-0.05% Tx-100 solution for 30 min. After blocking, antibodies raised against MT 1 (1:200, Santa Cruz sc-13179), MT 2 (1:1,000, ABIN122307, antibodies-online) and α 1 -adrenergic (1:500, Abcam ab3462) receptors were used. The rest of the protocol was similar to that elsewhere described using ad hoc secondary regents. PLA allows the ex vivo detection of molecular interactions between two endogenous proteins. PLA probes were obtained by linkage of primary anti-MT 1 or MT 2 receptor antibodies to PLUS oligonucleotide (DUO92009, Sigma, St. Louis, USA) and the α 1A -adrenergic antibody to MINUS oligonucleotide (DUO92010, Sigma, St. Louis, USA). Samples were analyzed using confocal microscope (Zeiss LSM 5, Jena, Germany) at 40X magnification. The rest of the protocol was performed as described elsewhere, red spots were counted in each of the ROIs obtained in the nuclei images and data analysis was performed using specific PLA software Martinez-Pinilla et al., 2017; Navarro et al., 2018) . . Interestingly, prazosin blocks the effect of melatonin on reducing IOP. As it is a α 1A -adrenoceptor (α 1A -AR) antagonist (Dubocovich, 1995; Huete-Toral et al., 2015; Pintor, Pelaez, Hoyle, & Peral, 2003) we hypothesized that melatonin and α 1A -adrenergic receptors (α 1A AR) could interact.
RESULTS
Melatonin and
Cognate heterotrimeric G proteins are G i for melatonin receptors, and G q/11 for α 1A -AR (www.guidetopharmacology.org). We then measured, in 59HCE ciliary body epithelial cells, cAMP levels and dynamic mass redistribution (DMR). The effect of MT 1 or MT 2 receptor agonists did not result in decreasing forskolin-induced cytosolic [cAMP] (Fig. 1A-B ). When cells were challenged with the α 1A AR agonist phenylephrine, a remarkable elevation of cytosolic forskolin-induced cAMP was achieved. The antagonist prazosin abolished the cAMP elevation produced by phenylephrine. We also assayed the canonical coupling of α 1A AR to heterotrimeric G q proteins. We however did not find any effect on Ca 2+ levels in 59HCE cells treated with phenylephrine ( Fig. 1C ). These results demonstrate that human ciliary epithelial cells express melatonin MT 1 and MT 2 , and α 1A -adrenergic receptors not coupled to cognate G proteins. Adrenoceptor mediated increases in cAMP reflect a Gs coupling able to overcome the effect of forskolin. It should be noted that the concentration of forskolin chosen for the assays (500 nM) is optimal as it allows detection of both Gi-and Gs-coupling.
To confirm atypical G protein coupling, similar assays were performed in the presence toxins that disrupt G s -or G i -mediated signaling. Results show that cholera but not pertussis toxin inhibited the action of agonists, unequivocally indicating G s involvement (Fig. 1D, 1E ). Interestingly, the presence of the α 1A -adrenergic antagonist, prazosin, abolished any effect of melatonergic agonists. Further evidence of cross-antagonism, a well-accepted heteromer print (Franco, Martinez-Pinilla, Lanciego, & Navarro, 2016) , was underscored using a label-free technique consisting of detecting cell dynamic mass redistribution (DMR). The signal induced by any agonist was relatively high, and the combination of phenylephrine and either melatonin (Fig. 1F ) or IIK7 ( Fig. 1G ), provided a more robust DMR response. As in cAMP determination assays, a cross-antagonism between α 1A AR and melatonin receptors was detected. When the experiments were carried out in the presence of cholera and pertussis toxins, responses were again abolished by cholera toxin (Fig. 1H-I ). Taken together, these results suggest that the crosstalk between melatonergic and α 1A -adrenergic receptors are solely due to coupling to G s .
Atypical signaling in ciliary cells is due to α 1A -adrenergic/melatonin receptor complexes
To identify potential direct interactions, a FRET biophysical approach was used ( Fig. 2A) Receptor functionality was first addressed in single transfected cells. Upon α 1A AR activation a robust increase in cytosolic [Ca 2+ ] detected by the fluorescence due to calcium-bound to an engineered GCaMP6 calmodulin sensor was obtained (Fig. 2D) . The agonist effect was inhibited by prazosin, but not by the melatonin receptor antagonists, luzindole or 4-PPDOT. Neither MT 1 nor MT 2 receptors were coupled to G q/11 in single-transfected cells (Fig. 2E-F) . Experiments of determination of forskolin-induced cAMP levels showed a G i -protein-coupling ( Fig. 2G-I ). The results confirm that, when expressed individually, receptors couple to their cognate G proteins. Activation of receptors in single transfected cells also provided significant DMR read-outs ( Fig. 2J-L) . Finally, BRET assays performed using β-arrestin-2-Rluc and receptors fused to YFP showed recruitment to either α 1A , MT 1 or MT 2 receptors when selective agonists were used ( Fig. 2M-O ).
G protein coupling was completely different in co-transfected cells (Fig. 3A-B) . On the one hand, phenylephrine did not produce Ca 2+ responses in cells expressing either α 1A -MT 1 Hets or α 1A -MT 2 Hets (Fig. 3C-D) . cAMP determination data in co-transfected cells were similar to the results obtained in 59HCE cells; agonists did not decrease forskolin-induced cAMP levels in cells expressing α 1A -MT 1 Hets or α 1A -MT 2 Hets. Also, cross-antagonism reappeared in cotransfected cells. Analogies between 59HCE and cotransfected HEK-293T cells were further found in experiments with toxins; the combined effect of agonists was blocked by cholera but not by pertussis toxin (Fig. 3E-F) . Also, matching results in 59HCE cells, a cross-antagonism and a potentiation of the label-free DMR signal were found upon co-activation, and cholera toxin did block the effect (Fig. 3G-J) . These results indicate a lack of productive coupling of receptor heteromers with G q/11 or G i . Cross-modulation was found in β-arrestin-2 recruitment but with a particular feature, namely both α 1A -receptor activation and activation of MT 1 melatonin receptors recruited β-arrestin to the α 1A -receptor, co-activation resulting in a stronger signal (Fig. 3K) .
Antagonists of the two receptors abolished recruitment induced by agonists (cross-antagonism was, therefore, found). Similar results were obtained in cells co-expressing α 1A -MT 2 heteroreceptor complexes using ad hoc agonists/antagonists (Fig. 3L ).
The glaucomatous eye has reduced heteroreceptor complex expression and altered signaling
First of all, identification of α 1A -MT 1 Hets and α 1A -MT 2 Hets was achieved in healthy and glaucomatous conditions. The in situ proximity ligation (PLA) technique is instrumental to detect receptor-receptor interactions in a native system. Red clusters coming from PLA assays proved the occurrence of both α 1A -AR/MT 1 R and α 1A -AR/MT 2 R complexes in 59HCE cells. The analysis of the PLA labeling provided values of 65±10 dots/nucleus in the case of the α 1A -MT 1 Hets and 73±8 dots/nucleus in the case of the MT 2 /α 1 heteromer. The percentage of cells that presented positive PLA was 56±4 for α 1A -MT 1 Hets and 57±5 for α 1A -MT 2 Hets (n=150).
Does eye hypertension correlate with altered expression of melatonin-adrenoceptor complexes? We approached this question using cells subjected to stimulation of the transient receptor potential vanilloid 4 (TRPV4) channel. As previously reported (H. A. Alkozi, Perez de Lara, Sanchez-Naves, H. A. Alkozi & Pintor, 2015) , activation of the channel mimics the ion fluxes that drive the increase in hydrostatic pressure that occurs in the hypertensive/glaucomatous eye. The application to 59HCE cells of the TRPV4 agonist, GSK1016790A, modified the PLA signal in a dose-dependent manner. As shown in Fig. 4A -B, the higher the concentration of GSK1016790A, the lower the PLA signal. Therefore, a reduction in the expression α 1A -MT 1 Hets or α 1A -MT 2 Hets happens when a glaucomatous condition is reproduced in a preclinical model (Fig. 4C ).
Heteromer expression was assayed in unique postmortem samples obtained from GP and agematched controls. In the eye from healthy donors, the presence of melatonin MT 1 , MT 2 and α 1A -adrenergic receptors was confirmed by immunoreactivity across the ciliary body ( Fig. 4D-F) . A strong labeling for the MT 1 R was present in non-pigmented epithelial cells, while the labeling for the MT 2 R was observed in the basal membrane of the non-pigmented epithelium (Fig. 4D-E) . Melatonin receptors were not found in the stroma. Concerning the α 1A -adrenergic receptor, a positive labeling was observed in the pigmented and non-pigmented epithelial cells as well as in the stroma (Fig. 4F) . Similar immunohistochemical studies carried out in samples obtained from GP showed altered receptor expression ( Fig. 4G-I ). The expression of the α 1 -adrenergic receptor showed a trend (to increase) that was not statistically significant (Fig. 4J) . In sharp contrast, immunoreactivity for melatonin receptors was markedly reduced, 81±15 and 54±13% for, respectively, MT 1 and MT 2 receptors. For MT 1 /α 1A and MT 2 /α 1A receptor pairs, a marked PLA positive labeling was observed in control samples ( Fig. 4K and 4M) . Remarkably, when PLA was performed in samples from GP, the reduction of heteromers was 88% in the case of the MT 1 /α 1A and 90 % in the case of the MT 2 /α 1A heteromers (Fig. 4L, 4N and 4O ). Once more, these results match with the results obtained in 59HCE cells treated with a TRPV4 activator to mimic a glaucoma-like condition.
A novel therapeutic approach to combat glaucoma
In GP eyes and in the eye of glaucomatous models, the coupling of α 1A -adrenoceptors to G q and the subsequent Ca 2+ signaling seems detrimental and markedly contributing to the disease.
Accordingly, an antagonist of α 1A -AR would be beneficial as a blocker of calcium production and of Ca 2+ -regulated chloride channels (Fleischhauer, Mitchell, Peterson-Yantorno, Coca-Prados, & Civan, 2001) . To test the hypothesis we moved to a well-established murine model of glaucoma (Perez de Lara et al., 2014). 3-month-old DBA/2J mice have normotensive eyes and physiological levels of melatonin. Retinal electrophysiology parameters were undistinguishable from those in the control mouse (C57BL/6 background) ( Fig. 5A-C) , however prazosin antagonized hypotensive effect of melatonin (Fig. 5D ). 9-month-old mice display a full glaucoma-like pathology (Fig. 5A-C) . At 9 months of age, and despite elevated levels of melatonin (Fig. 5B) , the glaucomatous eye of DBA/2J mice was sensitive to the hypotensive effect of exogenously added melatonin, which reduced the IOP from 16.6±0.6 to 11.8±0.4 mmHg. Remarkably, prazosin, enhanced melatonin hypotensive action (to 9.0 ± 0.5 mmHg) instead of antagonizing it (Fig. 5F) . Moreover, the effect of prazosin lasted more than 6 hours, thus indicating a very appropriate therapeutic time window. These results open a new and easy-to-implement anti-glaucoma treatment, consisting of melatonin/prazosin co-administration, with few expectable side effects.
Discussion
Current therapy of GP addresses symptoms by interventions neither efficacious in all patients nor absent of adverse events. Prostaglandin analogues have been approved for GP because they reduce intraocular pressure but by unknown mechanisms (Lanza et al., 2018; Sanford, 2014; Weinreb et al., 2015) . Blockers of ß-adrenoceptors or drugs able to engage α-adrenoceptors are in the portfolio; however, the rationale behind the hypotensive action of to ß-blockers and α-receptor agonists is unknown.
Melatonin, has become popular for potential properties for (among other) sleep induction and it is even on-line available. Already in 1993 (Serino, d'Istria, & Monteleone, 1993) described the production of melatonin in the pineal gland and in the retina by methylation of N-acetyl serotonin (Hardeland, 2010) . Interestingly, melatonin decreases IOP but the significant increase in the aqueous humour of GP is not enough to normalize IOP (Alarma-Estrany, Crooke, Peral, & Pintor, 2007 ; H. . Characterization of melatonin receptors has not been completed due to atypical pharmacological and non-fulfilled suspicions of a third receptor. We reasoned that atypical data could be due to interactions with other GPCRs as receptor heteromers display particular properties (Ferre et al., 2009 ). Here we selected α 1A -AR because its activation leads to increases in cytosolic [Ca 2+ ] that in turn control ion fluxes in the ciliary body. We here report that MT 1 and MT 2 receptors may directly interact with α 1A -ARs.
The role of epinephrine in the physiology of the eye is known since 1970 (Drance & Ross, 1970; Zalta, Shock, Stone, & Petursson, 1983) . Interestingly, the lack of coupling of receptors for epinephrine to G q/11 in the ciliary body (Figure 1 ), both intriguing and relevant, is due to α 1A -Rs forming heteromers with melatonin receptors. Remarkably, the glaucomatous eye expresses few functional units and the signaling mediated by Gq-coupled α 1A -ARs negatively impacts on IOP.
Our results predicted that the effect of melatonin would be enhanced by blockade of G q -coupled α 1A -adrenergic receptors by prazosin. Indeed, combination of the two compounds led to normalize IOP in a well-established model of glaucoma and the effect was not transient but lasted for 6 hours. The long lasting experience with prazosin as blood pressure lowering agent indicates that it is very safe and does not display the serious side effects provoked by other α-adrenergic receptor antagonists (Brogden, Heel, Speight, & Avery, 1977) .
In summary, we have discovered a trend in glaucoma consisting of the disruption of complexes formed by adrenergic and melatonin receptors. Such trend found in animal models of the disease and in samples from human eye (from GP and age-matched controls) makes ineffective the huge 3.2-fold increase in the concentration of melatonin in the glaucomatous eye. The physiological functional unit is coupled to a G s protein whereas the disassembly leads to α 1A -adrenergic receptors coupled to G q and to melatonin receptors coupled to G i . Increases in calcium via G q and decreases of cAMP via G i establish a vicious circle that negatively impacts on the ion channels controlling intraocular pressure. The mechanism consisting of allosteric interaction and shift of G protein coupling is quite noteworthy and explains one early finding in the laboratory that is included in the paper, namely the lack of calcium ion mobilization by phenylephrine in cells expressing α 1A -adrenoceptors (Fig. 1C) . Together, our findings provide a better understanding of the ciliary body physiology, completing a preclinical translational research addressed to combat glaucoma. Remarkably, a therapeutic strategy resulting from combining melatonin, sold as a supplement and lacking collateral effects even at high doses in the eye (Rosenstein et al., 2010; Sanchez-Barcelo, Mediavilla, Tan, & Reiter, 2010) , and prazosin, approved for the therapy of blood hypertension (Brogden et al., 1977; Mallorga, Buisson, & Sugrue, 1988; Singleton et al., 1989; Torvik & Madsbu, 1986) , could readily enter into clinical trials to assay for safety and efficacy in humans.
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The authors report no conflict of interest. . One-way ANOVA followed by Bonferroni's multiple comparison post-hoc test were used for statistical analysis. ***p<0.001. Concentrations in the assays were: 100 nM phenylephrine, 1 µM melatonin, 100 nM IIK7, 1 µM prazosin, 1 µM luzindole and 1 µM 4PPDOT. Immunolocalization of MT 1 (G), MT 2 (H) or α 1 -adrenergic (I) receptors in the ciliary body of GP. Quantitation (I) of results comparing patients and controls using fluorescence values taken in identical experimental conditions. Data, given in percentage (100% given to values from controls) are the mean ± SEM (n=4). **p<0.01 and ***p<0.001, using Student's t-test. Panels K-O: Determination by PLA of α 1 -adrenergic and either MT 1 (K) of MT 2 (M) receptor complexes in the ciliary body of age-matched IOP normotensive individuals. Determination by PLA of α 1 -adrenergic and either MT 1 (L) of MT 2 (N) receptor complexes in the ciliary body of GP. Quantitation (O) of clusters comparing data in GP and controls using fluorescence values taken in identical experimental conditions. Data, given in percentage (100% given to values from controls) are the mean ± SEM, n=4 (***p<0.001, using Student's t-test). values of control C57BL/6J and DBA/2J mice at 3 and 9 months of age. Data are the mean ± SEM (n=12). ***p<0.001 (Wilcoxon's test for paired samples). Panel B: Melatonin concentrations in the aqueous humour of C57BL/6J and DBA/2J mice at 3 and 9 months of age. Data are the mean ± SEM (n=6). ***p<0.001 (Wilcoxon's test for paired samples). Panel C: Electroretinogram in C57BL/6J (blue) and DBA/2J (red) mice. Positive scotopic threshold response (pSTR) amplitude was significantly reduced between 3 and 9 months of age (p<0.00001). Panels D-E: Time course of the effect on IOP in 3 (D) or 9 (E) month old DBA/2J mice after the instillation of melatonin ± prazosin. Data are the mean ± SEM (n=5). **p<0.01 (two-way ANOVA followed by post-hoc Tukey's test).
